TAAR2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue lysate, Primary antibody: P06622(TAAR2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06622(TAAR2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of TAAR2 Antibody**

TAAR2 (Trace Amine-Associated Receptor 2) is a G protein-coupled receptor (GPCR) belonging to the trace amine-associated receptor family. It is primarily expressed in the brain and binds trace amines, such as β-phenylethylamine and tyramine, which are structurally related to classical monoamine neurotransmitters. TAAR2 is implicated in modulating neurotransmitter systems, including dopamine and serotonin pathways, and has been linked to neuropsychiatric disorders like schizophrenia, depression, and bipolar disorder. However, its precise physiological role remains poorly understood due to low endogenous expression levels and overlapping functions with other TAAR subtypes.

TAAR2 antibodies are critical tools for studying the receptor's localization, expression patterns, and function in both normal and diseased states. These antibodies are typically developed against specific epitopes of the TAAR2 protein, such as extracellular or intracellular domains, and validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Reliable TAAR2 antibodies help elucidate its involvement in neural signaling, synaptic plasticity, and potential therapeutic targeting. Challenges include ensuring specificity due to structural similarities among TAAR family members and low receptor abundance. Recent advancements in antibody validation techniques, including knockout controls and peptide-blocking assays, have improved their reliability in neuroscience research.